Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. RGC
RGC logo

RGC Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
31.900
Open
31.060
VWAP
29.83
Vol
96.04K
Mkt Cap
14.48B
Low
28.320
Amount
2.87M
EV/EBITDA(TTM)
--
Total Shares
494.49M
EV
14.47B
EV/OCF(TTM)
--
P/S(TTM)
--
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Show More

Events Timeline

(ET)
2026-04-07
12:10:00
Regencell Bioscience Shares Down 10.7% to $27.52
select
2026-04-07
10:10:00
Regencell Bioscience Shares Down 7.1% to $28.64
select
2026-04-02 (ET)
2026-04-02
12:10:00
Regencell Bioscience Shares Down 9.5% to $30.50
select
2026-04-01 (ET)
2026-04-01
12:10:00
Regencell Bioscience Stock Rises 49.5% to $38.02
select
2026-04-01
10:10:00
Regencell Bioscience Stock Rises 23.9% to $31.50
select
2026-03-30 (ET)
2026-03-30
06:20:00
Regencell Bioscience Files to Sell Ordinary Shares
select
2026-03-23 (ET)
2026-03-23
12:10:00
Regencell Bioscience Shares Down 8.7% to $25.00
select
2026-03-18 (ET)
2026-03-18
12:10:00
Regencell Bioscience Stock Rises 15.4% to $26.50
select
2026-03-18
10:10:00
Regencell Bioscience Stock Rises 26.7% to $29.11
select

News

Globenewswire
7.0
16:46 PMGlobenewswire
Regencell Bioscience Faces Class Action Lawsuit
  • Class Action Initiated: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Regencell Bioscience Holdings Ltd., seeking damages for investors who purchased securities between October 28, 2024, and October 31, 2025, indicating serious legal risks for the company.
  • False Statements Allegations: The complaint alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose its vulnerability to market manipulation, which exposed investors to significant financial risks.
  • Increased Regulatory Risks: Due to the alleged false statements, Regencell faces heightened scrutiny from regulators and potential governmental enforcement actions, which could lead to substantial legal, financial, and reputational harm, impacting its future operations.
  • Investor Rights Protection: Investors have until June 23, 2026, to request to be appointed as lead plaintiff, with the law firm promising to charge fees only on a contingency basis if successful, ensuring that investors' rights are protected in the legal proceedings.
Globenewswire
7.0
05-09Globenewswire
Regencell Securities Class Action Notice
  • Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
  • Lawsuit Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to market manipulation and significant financial risks, thereby impacting the company's reputation and legal standing.
  • Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has achieved the largest securities class action settlement against a Chinese company, demonstrating its expertise and successful track record in this field.
  • Investor Action Advice: Investors can visit the Rosen Law Firm website or call the toll-free number for more information, encouraging them to choose qualified legal counsel to protect their rights and avoid inexperienced intermediaries.
Globenewswire
7.0
05-08Globenewswire
Regencell Bioscience Holdings Class Action Reminder for Investors
  • Class Action Reminder: Robbins LLP reminds all investors who purchased Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024, and October 31, 2025, that a class action has been filed to protect investor rights and seek compensation.
  • Allegations of Market Manipulation: The lawsuit alleges that Regencell was affected by market manipulation during the class period, leading to significant stock price volatility and exposing investors to substantial financial risks, while also subjecting the company to heightened regulatory scrutiny.
  • Expected Legal Costs: Regencell disclosed in an SEC filing that it received a subpoena from the U.S. Department of Justice due to recent market volatility, indicating that the company expects to incur significant legal costs and may have to pay fines exceeding its insurance coverage.
  • Stock Price Impact: Following this news, Regencell's stock price fell by $3.09, or 18.56%, closing at $13.56 per share on November 3, 2025, reflecting market uncertainty and a decline in investor confidence regarding the company's future prospects.
Globenewswire
7.0
05-08Globenewswire
Multiple Companies Face Class Action Lawsuits
  • LKQ Corporation Lawsuit: A class action lawsuit against LKQ Corporation alleges that from February 27, 2023, to July 23, 2025, executives failed to disclose significant risks related to customer losses at FinishMaster, which could negatively impact the company's reputation and stock price as investors suffered losses.
  • Regencell Bioscience Lawsuit: Regencell Bioscience Holdings Limited faces a class action lawsuit for the period from October 28, 2024, to October 31, 2025, where it is accused of failing to disclose market manipulation risks, exposing investors to financial risks and potential regulatory scrutiny, which could hinder future growth.
  • Globant S.A. Lawsuit: Globant S.A. is involved in a class action lawsuit covering February 15, 2024, to August 14, 2025, for not disclosing decreasing demand in Latin America and wage freezes, misleading investors about the company's prospects, which may have long-term negative effects on its market performance.
  • Investor Rights Reminder: The Law Offices of Frank R. Cruz remind affected investors of their rights to participate in these class actions, emphasizing the potential impact on future legal strategies and corporate governance structures.
Globenewswire
7.0
05-08Globenewswire
Regencell Faces Class Action Lawsuit Reminder
  • Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Regencell Bioscience Holdings Limited for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 28, 2024, and October 31, 2025, with a deadline to contact the firm by June 23, 2026.
  • Market Manipulation Risks: The complaint alleges that Regencell made false and misleading statements, resulting in significant stock volatility due to market manipulation, which exposed the company to regulatory scrutiny and reputational damage, thereby undermining investor confidence.
  • Loss Recovery Opportunity: Investors are encouraged to join the lawsuit to recover losses, as the Schall Law Firm specializes in securities class actions and offers free consultations to help affected shareholders understand their rights and take action.
  • Legal Proceedings Status: The class action has not yet been certified, meaning investors are not represented by an attorney until certification occurs; those who choose not to act will remain absent class members and may lose their opportunity to claim damages.
PRnewswire
7.0
05-06PRnewswire
Regencell Securities Class Action Notice
  • Class Action Deadline: Rosen Law Firm reminds investors who purchased Regencell securities between October 28, 2024, and October 31, 2025, that they must apply to be lead plaintiff by June 23, 2026, to participate in the class action and seek compensation.
  • Transparent Fee Structure: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, minimizing financial burdens for participants.
  • Firm's Track Record: Rosen Law Firm specializes in securities class actions and has achieved the largest settlement against a Chinese company, demonstrating its extensive experience and success in this legal domain.
  • Case Background: The lawsuit alleges that Regencell made false and misleading statements during the class period, exposing investors to significant financial risks and potential regulatory scrutiny, which could adversely affect the company's reputation and financial health.

Valuation Metrics

The current forward P/E ratio for Regencell Bioscience Holdings Ltd (RGC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Regencell Bioscience Holdings Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

okay give me some I can buy
Intellectia · 8 candidates
Market Cap: >= 10.00BRegion: USPrice: $5.00 - $60.00List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: >= $20.00Monthly Average Dollar Volume: >= 5,000,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
11.85B
AMKR logo
AMKR
Amkor Technology Inc
13.66B
SKM logo
SKM
SK Telecom Co Ltd
13.67B
SBS logo
SBS
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP
23.76B
STLA logo
STLA
Stellantis NV
29.78B
RGC logo
RGC
Regencell Bioscience Holdings Ltd
13.93B
stick of the week
Intellectia · 10 candidates
Market Cap: >= 10.00BRsi Category: moderateMoving Average Relationship: PriceAboveMA200Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
PL logo
PL
Planet Labs PBC
12.12B
SBAC logo
SBAC
SBA Communications Corp
22.64B
INTC logo
INTC
Intel Corp
254.58B
STX logo
STX
Seagate Technology Holdings PLC
96.19B
CIEN logo
CIEN
Ciena Corp
61.40B
LITE logo
LITE
Lumentum Holdings Inc
55.14B
what should I buy for swing trading
Intellectia · 426 candidates
Price: $10.00 - $150.00Rsi Category: moderateList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Month Price Change Pct: $5.00 - $40.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MLEC logo
MLEC
Moolec Science SA
5.05M
AEHR logo
AEHR
Aehr Test Systems
1.36B
BKSY logo
BKSY
Blacksky Technology Inc
1.14B
LUNR logo
LUNR
Intuitive Machines Inc
5.20B
KRRO logo
KRRO
Korro Bio Inc
201.92M
SNSE logo
SNSE
Sensei Biotherapeutics Inc
41.58M
top moving stocks
Intellectia · 31 candidates
Market Cap: >= 500.00MPrice: >= $2.00Price Change Pct: $-100.00 - $-5.00Relative Vol: >= 1.50List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 500,000
Ticker
Name
Market Cap$
top bottom
LNN logo
LNN
Lindsay Corp
1.22B
KNF logo
KNF
Knife River Corp
4.65B
OMER logo
OMER
Omeros Corp
869.71M
WIX logo
WIX
Wix.Com Ltd
5.28B
IRWD logo
IRWD
Ironwood Pharmaceuticals Inc
635.93M
PBH logo
PBH
Prestige Consumer Healthcare Inc
2.73B
stocks gain $5.00 in 2026
Intellectia · 2622 candidates
Year Price Change Pct: >= $0.01
Ticker
Name
Market Cap$
top bottom
AXTI logo
AXTI
AXT Inc
3.80B
PTN logo
PTN
Palatin Technologies Inc
35.18M
RGC logo
RGC
Regencell Bioscience Holdings Ltd
12.08B
RLMD logo
RLMD
Relmada Therapeutics Inc
639.83M
BW logo
BW
Babcock & Wilcox Enterprises Inc
1.95B
TERN logo
TERN
Terns Pharmaceuticals Inc
5.44B
bullish stocks this week
Intellectia · 56 candidates
Market Cap: >= 4.00BRegion: USList Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
MASI logo
MASI
Masimo Corp
9.43B
IBRX logo
IBRX
Immunitybio Inc
8.41B
ONDS logo
ONDS
Ondas Inc
4.98B
MRNA logo
MRNA
Moderna Inc
18.21B
ELF logo
ELF
elf Beauty Inc
5.20B
KTOS logo
KTOS
Kratos Defense and Security Solutions Inc
17.84B
ابي سهم التارقت حقي يكون اجيب فوق 25% واعلى من راس مالي
Intellectia · 1346 candidates
Year Price Change Pct: >= $25.00
Ticker
Name
Market Cap$
top bottom
RGC logo
RGC
Regencell Bioscience Holdings Ltd
13.54B
PTN logo
PTN
Palatin Technologies Inc
28.78M
ANPA logo
ANPA
Rich Sparkle Holdings Ltd
875.38M
ABVX logo
ABVX
Abivax SA
8.86B
SNDK logo
SNDK
Sandisk Corp
97.55B
HYMC logo
HYMC
Hycroft Mining Holding Corporation
3.20B
what’s a good buy for day trading
Intellectia · 2418 candidates
Region: USPrice: $2.00 - $200.00Volume: >= 200,000List Exchange: XNYS, XNAS, XASE
Ticker
Name
Market Cap$
top bottom
AZN logo
AZN
AstraZeneca PLC
298.35B
PLAG logo
PLAG
Planet Green Holdings Corp
30.35M
AQST logo
AQST
Aquestive Therapeutics Inc
509.36M
CATX logo
CATX
Perspective Therapeutics Inc
351.47M
ASTI logo
ASTI
Ascent Solar Technologies Inc
29.36M
PAVM logo
PAVM
PAVmed Inc
9.16M
entonces que acciones?
Intellectia · 74 candidates
Market Cap: >= 3.00BRsi Category: moderateWeek Price Change Pct: $5.00 - $20.00Ema 20: >= -100Ema 60: >= -100Monthly Average Dollar Volume: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
SSL logo
SSL
Sasol Ltd
4.76B
LMND logo
LMND
Lemonade Inc
6.97B
TEO logo
TEO
Telecom Argentina SA
5.50B
SBS logo
SBS
Companhia de Saneamento Basico do Estado de Sao Paulo - SABESP
18.55B
KEP logo
KEP
Korea Electric Power Corp
27.73B
PKX logo
PKX
Posco Holdings Inc
19.18B
pE <10
Intellectia · 2866 candidates
Pe Ttm: <= 10
Ticker
Name
Market Cap$
top bottom
SLG logo
SLG
SL Green Realty Corp
3.35B
AVDL logo
AVDL
Avadel Pharmaceuticals PLC
2.11B
HUBS logo
HUBS
HubSpot Inc
15.84B
ARWR logo
ARWR
Arrowhead Pharmaceuticals Inc
9.42B
PDFS logo
PDFS
PDF Solutions Inc
1.42B
TRVG logo
TRVG
Trivago NV
197.86M

Whales Holding RGC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Regencell Bioscience Holdings Ltd (RGC) stock price today?

The current price of RGC is 29.28 USD — it has decreased -6.96

What is Regencell Bioscience Holdings Ltd (RGC)'s business?

Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.

What is the price predicton of RGC Stock?

Wall Street analysts forecast RGC stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for RGC is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Regencell Bioscience Holdings Ltd (RGC)'s revenue for the last quarter?

Regencell Bioscience Holdings Ltd revenue for the last quarter amounts to NaN USD, decreased

What is Regencell Bioscience Holdings Ltd (RGC)'s earnings per share (EPS) for the last quarter?

Regencell Bioscience Holdings Ltd. EPS for the last quarter amounts to USD, decreased

How many employees does Regencell Bioscience Holdings Ltd (RGC). have?

Regencell Bioscience Holdings Ltd (RGC) has 10 emplpoyees as of May 10 2026.

What is Regencell Bioscience Holdings Ltd (RGC) market cap?

Today RGC has the market capitalization of 14.48B USD.